Dr. Farhad Ravandi Discusses Vosaroxin in the VALOR Trial
December 7th 2014Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center in Houston, describes results from the phase III VALOR trial that explored vosaroxin plus cytarabine versus placebo and cytarabine in patients with first relapsed or refractory acute myeloid leukemia.
Read More